Clinical Trial Update: Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy [Phase 1]

View source ↗

Summary

Phase 1 safety study of 212Pb-TCMC-Trastuzumab radioimmunotherapy has completed, evaluating safety in multiple HER2-expressing cancers. The investigation covers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Peritoneal Cancer
• Stomach Cancer

Drugs mentioned

• 212Pb-TCMC-Trastuzumab (lead-212 labeled trastuzumab radioimmunotherapy)

Snippet

Sponsor: Orano Med LLC | Conditions: Breast Neoplasms, Peritoneal Neoplasms | Phase 1 | Status: COMPLETED